Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-Abbvie Presents Positive Data From Phase 3 Study Of Major Depressive Disorder Treatment

BY Reuters
— 8:49 AM ET 05/23/2022

May 23 (Reuters) - Abbvie Inc (ABBV):

* ABBVIE PRESENTS POSITIVE DATA FROM PHASE 3 STUDY OF CARIPRAZINE (VRAYLAR®) FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER AT 2022 APA ANNUAL MEETING Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More ABBV News

AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
PR Newswire - 8:00 AM ET 05/23/2022
EMA's CHMP Recommends AbbVie's Upadacitinib For Ulcerative Colitis
Benzinga - 7:01 AM ET 05/23/2022
BRIEF-AbbVie Inc Says CHMP Recommends European Commission Approval Of Upadacitinib For Treatment Of Adults With Moderate To Severe Ulcerative Colitis
Reuters - 2:05 AM ET 05/23/2022